Matilde Aguilar-Moncayo

Matilde Aguilar-Moncayo

Auto-generated profile, based on publicly available information

Matilde Aguilar-Moncayo

Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Catalysis Today
Verified
Journal Article
Closed access
MLMaría Carmen Hidalgo López
María Carmen Hidalgo López
MAM. Aguilar
M. Aguilar
MMM. Maicu
M. Maicu
J.A. NavioJ.A. Navio
J.A. Navio
GIGerardo Ibañez
Gerardo Ibañez

17 November 2009 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
ZLZhuo Luan
Zhuo Luan
KHKatsumi Higaki
Katsumi Higaki
MAMatilde Aguilar‐Moncayo
Matilde Aguilar‐Moncayo
HNHaruaki Ninomiya
Haruaki Ninomiya
KOKousaku Ohno
Kousaku Ohno
YSYoshiyuki Suzuki
Yoshiyuki Suzuki

1 March 2013 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
TTTomoko Takai
Tomoko Takai
KHKatsumi Higaki
Katsumi Higaki
MAMatilde Aguilar-Moncayo
Matilde Aguilar-Moncayo
TMTeresa Mena-Barragán
Teresa Mena-Barragán
YHYuki Hirano
Yuki Hirano
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
Lysosomal β-galactosidase (β-Gal) deficiency causes a group of disorders that include neuronopathic GM1 gangliosidosis and non-neuronopathic Morquio B disease. We have previously proposed the use of small molecule ligands of β-Gal as pharmacological chaperones (PCs) for the treatment of GM1 gangliosidosis brain pathology. Although it is still under development, PC therapy has yielded promising preclinical results in several lysosomal diseases. In this study, we evaluated the effect of bicyclic 1-deoxygalactonojirimycin (DGJ) derivative of the sp2-iminosugar type, namely 5N,6S-(N′-butyliminomethylidene)-6-thio-1- deoxygalactonojirimycin (6S-NBI-DGJ), as a novel PC for human mutant β-Gal. In vitro, 6S-NBI-DGJ had the ability to inhibit the activity of human β-Gal in a competitive manner and was able to protect this enzyme from heat-induced degradation. Computational analysis supported that the rigid glycone bicyclic core of 6S-NBI-DGJ binds to the active site of the enzyme, with the aglycone N′-butyl substituent, in a precise E-orientation, located at a hydrophobic region nearby. Chaperone potential profiling indicated significant increases of enzyme activity in 24 of 88 β-Gal mutants, including four common mutations. Finally, oral administration of 6S-NBI-DGJ ameliorated the brain pathology of GM1 gangliosidosis model mice. These results suggest that 6S-NBI-DGJ is a novel PC that may be effective on a broad range of β-Gal mutants.

1 May 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HSHironori Suzuki
Hironori Suzuki
UOUmeharu Ohto
Umeharu Ohto
KHKatsumi Higaki
Katsumi Higaki
TMTeresa Mena-Barragán
Teresa Mena-Barragán
MAMatilde Aguilar-Moncayo
Matilde Aguilar-Moncayo
TSToshiyuki Shimizu
Toshiyuki Shimizu
GM1 gangliosidosis and Morquio B disease are autosomal recessive diseases caused by the defect in the lysosomal β-galactosidase (β-Gal), frequently related to misfolding and subsequent endoplasmic reticulum-associated degradation. Pharmacological chaperone (PC) therapy is a newly developed molecular therapeutic approach by using small molecule ligands of the mutant enzyme that are able to promote the correct folding and prevent endoplasmic reticulum-associated degradation and promote trafficking to the lysosome. In this report, we describe the enzymological properties of purified recombinant human β-GalWT and two representative mutations in GM1 gangliosidosis Japanese patients, β-GalR201C and β-GalI51T. We have also evaluated the PC effect of two competitive inhibitors of β-Gal. Moreover, we provide a detailed atomic view of the recognition mechanism of these compounds in comparison with two structurally related analogues. All compounds bind to the active site of β-Gal with the sugar-mimicking moiety making hydrogen bonds to active site residues. Moreover, the binding affinity, the enzyme selectivity, and the PC potential are strongly affected by the mono- or bicyclic structure of the core as well as the orientation, nature, and length of the exocyclic substituent. These results provide understanding on the mechanism of action of β-Gal selective chaperoning by newly developed PC compounds.

9 May 2012 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
MAM. Aguilar-Moncayo
M. Aguilar-Moncayo
TTT. Takai
T. Takai
KHKatsumi Higaki
Katsumi Higaki
TMT. Mena-Barragán
T. Mena-Barragán
YHY. Hirano
Y. Hirano
YSY. Suzuki
Y. Suzuki
Competitive inhibitors of either α-galactosidase (α-Gal) or β-galactosidase (β-Gal) with high affinity and selectivity have been accessed by exploiting aglycone interactions with conformationally locked sp2-iminosugars. Selected compounds were profiled as potent pharmacological chaperones for mutant lysosomal α- and β-Gal associated with Fabry disease and GM1 gangliosidosis.

22 May 2009 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
MAMatilde Aguilar-Moncayo
Matilde Aguilar-Moncayo
TGTracey M. Gloster
Tracey M. Gloster
JTJohan Turkenburg
Johan Turkenburg
MMM. Isabel Garcia Moreno
M. Isabel Garcia Moreno
CMCarmen Ortiz Mellet
Carmen Ortiz Mellet
JFJosé M. García Fernández
José M. García Fernández
Synthesis of a panel of iso(thio)urea-type ring-modified castanospermine analogues bearing a freely mutarotating pseudoanomeric hydroxyl group results in tight-binding β-glucosidase inhibitors with unusual binding signatures; the presence of an N-octyl substituent imparts a remarkable anomeric selectivity, promoting strong binding of the appropriate β-anomer by the β-glucosidase.